This study was designed to investigate the putative protective effect of β-casomorphin-7 on
diabetic nephropathy in a rat model, and to explore the possible mechanism of this effect. SD rats were randomly divided into the following three groups: control group, diabetes group and β-casomorphin-7-treatment group. All rats were euthanized after 30 days with or without β-casomorphin-7 treatment. Biochemical parameters including
blood glucose and renal function were quantified. The concentration of plasma TGF-β1 was measured by ELISA. Histopathological changes to the kidney were studied by Masson and Sirius red staining. Expressions of α-smooth muscle actin (α-SMA),
E-cadherin,
vimentin, cytokeratin19 and TGF-β1
mRNA in rat renal cortices were analyzed by real-time PCR. Changes in α-SMA and
E-cadherin protein expression in rat renal cortices were quantified by Western blot. β-Casomorphin-7 treatment of diabetic rats reduced urinary
glucose, urinary
protein, serum creatinine, blood urinary
nitrogen, plasma TGF-β1 and the ratio of kidney:
body weight. Masson and Sirius red staining showed that β-casomorphin-7 treatment attenuated renal interstitial
fibrosis in diabetic rats. Compared to the control rats, diabetic rats had elevated expressions of α-SMA,
vimentin and TGF-β1
mRNA and α -SMA
protein and decreased expression of
E-cadherin and cytokeratin19
mRNA, and
E-cadherin protein. β-Casomorphin-7 treatment of diabetic rats partially normalized these changes. Our results suggest that administration of β-casomorphin-7 attenuates renal interstitial
fibrosis caused by diabetes. This protective effect may be associated, in part, with down regulation of epithelial-mesenchymal transition of renal tubular epithelial cells.